Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Hot AXIOS™ para drenaje de vías biliares en estenosis maligna (RAINBOW)

10 de noviembre de 2026 actualizado por: Boston Scientific Corporation

Estudio prospectivo francés sobre el drenaje de las vías biliares guiado por ecografía endoscópica en pacientes con estenosis biliar maligna (RAINBOW)

The study is designed to highlight the effectiveness of the Hot AXIOS™ stent when used in accordance with standard medical practice on the evolution of the quality of life of patients with malignant biliary stenosis requiring drainage of the bile ducts after failure of ERCP, in the two months after stent placement.

Descripción general del estudio

Descripción detallada

The study will evaluate the quality of life in patients with malignant biliary obstruction after the placement of a lumen-apposing metal stent via endoscopic ultrasound, with an emphasis on the improvement of quality of life measured as a reduction in jaundice. Improvement in jaundice is a direct indicator of effective bile drainage and is expected to correlate with an enhancement in overall quality of life. Quality of life will be measured by means of subject response to the EORTC QLQ-BIL21, a component of the European Organization for Research and Treatment of Cancer (EORTC) designed specifically to assess the quality of life in patients with biliary tract cancer. The QLQ-BIL21 consists of 21 questions which aim to evaluate specific symptoms and issues relevant to patients with biliary tract cancer, such as jaundice, pain, digestive problems and the psychosocial impact of the disease.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

162

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Besançon, Francia, 25030
        • CHU de Besançon
      • Cornebarrieu, Francia, 31700
        • Clinique des Cedres, Ramsay Sante
      • Limoges, Francia, 87042
        • CHU Limoges
      • Lyon, Francia, 69008
        • Hopital Prive Jean Mermoz
      • Nantes, Francia, 44300
        • Clinique Jules Verne
      • Nice, Francia, 06202
        • CHU Nice
      • Paris, Francia, 75012
        • Hopital Saint Antoine
      • Paris, Francia, 75908
        • Hopital Europeen Georges-Pompidou
      • Paris, Francia, 75014
        • Hopital Paris Saint-Joseph
      • Poitiers, Francia, 86021
        • CHU de Poitiers
      • Reims, Francia, 51092
        • CHU Reims
      • Rennes, Francia, 35033
        • CHRU Hopital Pontchaillou
      • Rouen, Francia, 76000
        • Clinique Saint-Hilaire
      • Saint-Herblain, Francia, 44800
        • Santé Atlantique
      • Strasbourg, Francia, 67091
        • CHU de Strasbourg
      • Toulouse, Francia, 31059
        • CHU Rangueil
      • Vandœuvre-lès-Nancy, Francia, 54500
        • CHRU de Nancy
      • Vichy, Francia, 03200
        • Centre Hospitalier de Vichy

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Patients 18 years or older
  2. Willing and able to comply with study procedures and provide written informed consent
  3. Patients with failed ERCP for treatment of suspected malignant biliary obstruction
  4. Patients for whom an indication for Hot AXIOS™ stent placement has been determined

Exclusion Criteria:

  1. Women who are pregnant, nursing or planning to become pregnant during the study
  2. Patients with immediately resectable tumor or resectable during the two months of the study
  3. Patients for whom the placement of a double pigtail prosthesis is planned by the investigator during the index procedure
  4. Current participation in another investigation drug or device study that could interfere with the endpoints of this study
  5. Persons under guardianship or curatorship

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Hot AXIOS™ Recipients

The Hot AXIOS™ Stent is a flexible, fully covered self-expanding metal stent that is preloaded within the Electrocautery Enhanced Delivery System. Patients who meet all eligibility criteria will receive the Hot AXIOS™stent and their quality of life will be measured at baseline, two weeks after stent placement and two months after stent placement by the jaundice dimension of the EORTC QLQ-BIL21 questionnaire. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study.

The Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System is commercially available and can be used to bridge two lumens or organs to create an internal drain, so as to drain the bile ducts in case of failure of ERCP.

Otros nombres:
  • Caliente AXIOS™

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Quality of Life Measurement - Jaundice Dimension
Periodo de tiempo: 2 months (± 15 days)

The primary outcome is the difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the jaundice dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much); the jaundice dimension consists of three of those questions. A lower score correlates to fewer symptoms or problems.

2 months (± 15 days)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Quality of Life Measurement - Non-Jaundice Dimension
Periodo de tiempo: 2 months (± 15 days)

The absolute difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the non-jaundice dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much); the non-jaundice dimension consists of 18 of those questions. A lower score correlates to fewer symptoms or problems.

2 months (± 15 days)
Quality of Life Measurement - Global Score
Periodo de tiempo: 2 months (± 15 days)

The absolute difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the global score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much). A lower score correlates to fewer symptoms or problems.

2 months (± 15 days)
Reduction in Bilirubin (Clinical Success)
Periodo de tiempo: 2 weeks (+ 7 days) and 2 months (± 15 days)

Clinical success is defined as a reduction in bilirubin > 50% at each follow-up compared to baseline.

2 weeks (+ 7 days) and 2 months (± 15 days)
Rate of Resolution of Clinical Symptoms
Periodo de tiempo: 2 months (± 15 days)

Resolution of GOO-related clinical symptoms such as jaundice, nausea/vomiting, fever/chills, weight loss and abdominal pain following implant of Hot AXIOS™ at 2 months of follow-up

2 months (± 15 days)
Rate of Reintervention
Periodo de tiempo: 2 months (± 15 days)

Reintervention is defined as endoscopic, radiological or surgical intervention for the management of recurrent biliary obstruction due to stent dysfunction (e.g., obstruction or migration) at 2 months of follow-up. This criterion will be measured within the population for whom the placement of the Hot AXIOS™ stent was a technical success.

2 months (± 15 days)
Chemotherapy Status
Periodo de tiempo: 2 months (± 15 days)

Number of days after study stent implantation to start or continuation of chemotherapy (if applicable).

2 months (± 15 days)
Overall Survival
Periodo de tiempo: 2 months (± 15 days)

Time from the placement of the Hot AXIOS™ to the date of death from any cause or to the end of follow-up (end of study participation or lost to follow-up) to assess summary measure overall survival.

2 months (± 15 days)
Progression-Free Survival
Periodo de tiempo: 2 months (± 15 days)

Time from the placement of the Hot AXIOS™ to the earliest date of either disease progression or death from any cause or to the end of follow-up (end of study participation or lost to follow-up) to assess summary measure progression-free survival.

2 months (± 15 days)
Number of Days Alive after Hospital Discharge
Periodo de tiempo: 2 months (± 15 days)

Number of days alive after hospital discharge within 2 months after the placement of the Hot AXIOS™.

2 months (± 15 days)
Rate of Technical Success
Periodo de tiempo: 2 months (± 15 days)

Technical success is defined as the successful placement of the Hot AXIOS™ stent during study procedure.

2 months (± 15 days)
Serious Adverse Events
Periodo de tiempo: 2 months (± 15 days)

Serious adverse events related to the study procedure and/or the Hot AXIOS™ stent.

2 months (± 15 days)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Jean-Baptiste Chevaux, Central Hospital, Nancy, France

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de junio de 2025

Finalización primaria (Estimado)

1 de mayo de 2027

Finalización del estudio (Estimado)

1 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

2 de diciembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

19 de diciembre de 2024

Publicado por primera vez (Actual)

27 de diciembre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • E7209

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir